Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron chelation.

C Hershko1, A Pinson, G Link

  • 1Department of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.

Blood Reviews
|March 1, 1990
PubMed
Summary
This summary is machine-generated.

Iron chelation therapy significantly improves survival in thalassemia patients, reducing cardiac mortality. New oral iron chelators show promise, potentially replacing desferrioxamine (DF) in future treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early exposure to Aroclor 1254 in vivo disrupts the functional synaptic development of newborn hippocampal granule cells.

The European journal of neuroscience·2016
Same author

[Cystocele and perineal ultrasound : Comparison of reliability and patient satisfaction].

Der Urologe. Ausg. A·2016
Same author

Exposure to endocrine disrupting chemicals and neurodevelopmental alterations.

Andrology·2016
Same author

[Endocrine disruption: a challenge in research, public health and clinical practice].

Revue medicale de Liege·2015
Same author

Photoregulation of psbA transcript levels in mustard cotyledons.

Photosynthesis research·2014
Same author

The ribosomal RNA genes from chloroplasts of mustard (Sinapis alba L.): mapping and sequencing of the leader region.

Plant molecular biology·2013

Area of Science:

  • Hematology
  • Pharmacology
  • Cardiology

Background:

  • Thalassemia treatment relies on iron chelation to manage iron overload.
  • Desferrioxamine (DF) has improved survival rates but requires intensive administration.
  • Cardiac complications remain a significant concern in thalassemia patients.

Purpose of the Study:

  • To review the impact of iron chelation therapy on thalassemia outcomes.
  • To discuss current and emerging iron chelation strategies.
  • To explore novel applications of iron chelators beyond iron overload.

Main Methods:

  • Review of long-term desferrioxamine (DF) therapy protocols.
  • Analysis of DF efficacy in established cardiomyopathy.
  • Examination of experimental uses of DF in inflammatory conditions and protozoal infections.

Related Experiment Videos

  • Overview of research into orally effective iron chelators.

    • Main Results:

    • Adequate iron chelation has dramatically improved survival, reducing cardiac mortality and increasing life expectancy.
    • Early initiation of DF (2-4 years) and optimized administration (subcutaneous, IV) are crucial.
    • Continuous IV DF can improve myocardial function in patients with cardiomyopathy.
    • DF shows potential in non-iron overload conditions by preventing free-radical formation and inhibiting cell proliferation.
    • Several orally effective iron chelators superior to DF have been identified and are undergoing toxicity testing.

    Conclusions:

    • Iron chelation therapy is vital for improving survival and quality of life in thalassemia.
    • Optimized DF administration and novel therapeutic applications are expanding its utility.
    • Development of orally effective iron chelators represents a significant advancement, with promising candidates nearing clinical use.